Tezepelumab Rewires Epithelial Inflammation in Uncontrolled Asthma
Tezepelumab did more than blunt airway inflammation in this ex vivo asthma study. It shifted how bronchial epithelial cells responded to a viral mimic and, in parallel, changed the signal those cells sent to airway smooth muscle.
The work focused on TSLP blockade in patients with uncontrolled asthma and asked a mechanistic question that matters at the bedside: what happens inside the airway epithelium when upstream alarmin signaling is interrupted? Using bronchial epithelial cells collected before and after 12 weeks of tezepelumab or placebo, investigators traced changes in transcription, inflammatory pathway activation, and downstream remodeling signals delivered to bronchial smooth muscle cells.
The epithelial response was not uniform across the cohort. It was strongest in patients who entered the study with higher baseline inflammatory activity, which fits the biology of an alarmin-driven disease state. In those patients, interrupting TSLP appears to have dampened a program that normally amplifies innate immune signaling after viral challenge.
Viral Mimic Stimulation Revealed a NF-κB-Linked Shift
The model used poly(I:C), a synthetic double-stranded RNA analog that reproduces a viral sensing signal in airway epithelial cells. After that stimulus, transcriptomic analysis showed enrichment of TNF-α and NF-κB-related pathways in placebo-treated cells compared with cells from the tezepelumab arm. In plain terms, epithelial cells retained a more inflammatory viral-response signature when TSLP was left intact.
Two calgranulin genes stood out early. In unstimulated bronchial epithelial cells, tezepelumab downregulated S100A8 and S100A9, genes that encode the calprotectin heterodimer linked to innate immune amplification through TLR4 and RAGE signaling. Their suppression is biologically meaningful because calprotectin can intensify epithelial alarm signaling and feed forward into tissue inflammation.
A single sentence captures the central mechanistic move: tezepelumab lowered the epithelial drive toward amplification.
Validation work pointed in the same direction, although the response varied across donors. The attenuation of inflammatory signaling was seen mainly in patients with higher baseline inflammatory responses, reinforcing the idea that the drug’s epithelial effect depends on the inflammatory state present before treatment.
TSLP Amplified S100 Genes and NF-κB Activation in Gain-of-Function Experiments
The ex vivo clinical observations were paired with gain-of-function experiments designed to test causality. Recombinant TSLP increased poly(I:C)-induced expression of S100A8, S100A9, TNFSF15, and TRAF1, while also increasing NF-κB activation.
This is the molecular logic that makes the clinical result plausible. TSLP sits upstream of multiple epithelial danger pathways, and when it is present during a viral-like stimulus, the cell does not simply respond; it escalates. The rise in TNFSF15 and TRAF1 also points to broader engagement of inflammatory and signaling networks linked to immune activation and transcriptional control.
The NF-κB signal matters because it is one of the central switches for inflammatory gene expression in the airway. When that pathway is activated, epithelial cells can sustain a proinflammatory state that helps maintain symptoms, promotes exacerbation-prone biology, and fuels crosstalk with adjacent structural cells.
Epithelial Conditioned Media Carried a Lower Remodeling Signal to Smooth Muscle
The study moved beyond epithelial transcription and asked whether those epithelial changes altered the behavior of bronchial smooth muscle cells. Conditioned media from poly(I:C)-stimulated epithelial cells collected after tezepelumab treatment induced lower TGF-β2 gene expression in smooth muscle cells than conditioned media from placebo-treated cells.
That finding places airway remodeling in direct conversation with alarmin blockade. TGF-β2 is a remodeling-associated mediator, and lower induction in smooth muscle cells suggests that the epithelial secretome after TSLP blockade becomes less able to instruct mesenchymal remodeling programs. In a disease defined by airway hyperresponsiveness and structural change, this kind of epithelial-to-mesenchymal signaling shift may be as important as the immediate anti-inflammatory effect.
The experimental design strengthens the interpretation. The smooth muscle cells were exposed not to the antibody itself, but to what epithelial cells secreted after treatment, which means the signal passed through the epithelial layer first. In clinical terms, that makes tezepelumab look less like a simple suppressor of one cytokine and more like a modifier of the airway ecosystem.
What This Means for Uncontrolled Asthma Biology
The study links an approved biologic to a set of epithelial changes that extend from innate antiviral sensing to downstream remodeling signals. Tezepelumab reduced epithelial expression of S100A8 and S100A9, blunted inflammatory pathway enrichment after poly(I:C) challenge, and reduced the ability of epithelial conditioned media to induce TGF-β2 in smooth muscle cells.
That sequence is clinically relevant because uncontrolled asthma is not driven by a single cell type. The airway epithelium senses viral triggers, releases alarmins, and communicates with mesenchymal cells that shape airflow limitation and tissue remodeling. By blocking TSLP, the treatment appears to interrupt that communication at an upstream node.
The cohort size was small, and the validation analyses showed donor-to-donor variability, so these data should be treated as hypothesis-generating rather than definitive. Even so, the pattern is internally consistent: higher baseline inflammation predicted more obvious attenuation, recombinant TSLP recapitulated inflammatory amplification, and epithelial-to-smooth muscle signaling shifted in a remodeling-suppressive direction after treatment.
The mechanistic picture remains incomplete, and the clinical biomarker question is still open. The study does not establish which patient subgroups will derive the greatest epithelial remodeling benefit, nor does it prove that the transcriptional changes translate into durable structural improvement in vivo. What it does show is that tezepelumab alters airway epithelial transcriptional responses in a way that reaches beyond symptom control and into the biology of airway remodeling itself.